Clinical trial
Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell…
NCT00051012 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00051012 |
|---|---|
| Title | Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients |
| Official title | A Multicenter Open-Label Study to Evaluate the Safety and Efficacy of DAB389IL-2 in Cutaneous T-Cell Lymphoma (CTCL) Patients Following Protocol 93-04-10, Protocol 93-04-11, or Protocol 92-04-01 or Who Meet the Requirements for Protocol 93-04-11 Except Have Biopsy-Documented CTCL That Does Not… |
| Lead sponsor | Eisai Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Sezary Syndrome |
| Intervention type | Drug |
| Interventions | ONTAK |
| Enrollment | 86 |
| Start date | Sep 1, 1995 |
| Primary completion | Oct 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Jan 3, 2003 |
| Last update posted | Mar 5, 2008 |
| Countries | Australia, Austria, Canada, Germany, Poland, Russia, Switzerland, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: